: +31 (0) 317 453 908
: info@check-points.com

Home | About Us | Company News | Evaluation of Check-MDR CT102 published in Journal of Clinical Microbiology
"It provided definitive results within the same working day, allowing rapid implementation of isolation measures and appropriate antibiotic treatment"

Naas et al.

Antimicrobial Agents and Chemotherapy, 2010

Evaluation of Check-MDR CT102 published in Journal of Clinical Microbiology

Published on: Feb 18, 2011

Check-MDR CT102, which detects carbapenemases (KPC, NDM-1, VIM, IMP and OXA-48) as well as ESBLs (CTX-M, TEM and SHV), was found to have a sensitivity and specificity of 100%.

Detection of carbapenemases based on susceptibility testing is complicated by the fact that bacteria carrying carbapenemases sometimes do not appear to be resistant to carbapenemases. This is especially true for carbapenemases NDM-1 and OXA-48. The consequences may be that the appropriate treatment is not administered and that proper infection control measures are not implemented.

Using a molecular test to pinpoint the presence of carbapenemase genes is therefore essential for the accurate detection of carbapenemases. By identifying the genes involved, Check-MDR CT102 also enables you to quickly obtain information to guide infection control measures and helps you to create an overview of your resisstance situation.


The evaluation is published ahead of print on the website of Journal of Clinical Microbiology. Click here to access the article.

Back to news list


newsletter

Thank you for your interest!

The Check-Points newsletter helps you to stay updated on the the latest developments in gram negative antibiotic resistance.

Sent on a quarterly basis, the newsletter features the latest news from Check-Points as well as summaries of key publications in the field and links to relevant news stories. Special issues will appear for ICAAC and ECCMID.

Subscribe below: